MADRID, Spain—Even with stringent patient selection and painstaking trial roll-in, macitentan (Actelion) does not appear to be beneficial in patients who have heart failure with preserved ejection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback